Table 1.
Participant Demographics of the Safety Population
| Characteristic | Vaccine Group, as Administered | ||||
|---|---|---|---|---|---|
| RSVpreF 120 μg/Placebo (na=141) | RSVpreF 120 μg/Tdap (na=141) | RSVpreF 240 μg + Al(OH)3/Placebo (na=142) | RSVpreF 240 μg + Al(OH)3/Tdap (na=144) | Placebo/Tdap (na=141) | |
| Sex, nb (%) | |||||
| Female | 141 (100.0) | 141 (100.0) | 142 (100.0) | 144 (100.0) | 141 (100.0) |
| Race, nb (%) | |||||
| White | 100 (70.9) | 98 (69.5) | 101 (71.1) | 107 (74.3) | 97 (68.8) |
| Black or African American | 29 (20.6) | 28 (19.9) | 25 (17.6) | 29 (20.1) | 38 (27.0) |
| Asian | 12 (8.5) | 9 (6.4) | 10 (7.0) | 5 (3.5) | 5 (3.5) |
| American Indian or Alaska Native | 0 | 2 (1.4) | 1 (0.7) | 0 | 1 (0.7) |
| Native Hawaiian or other Pacific Islander | 0 | 1 (0.7) | 2 (1.4) | 1 (0.7) | 0 |
| Multiracial | 0 | 2 (1.4) | 3 (2.1) | 1 (0.7) | 0 |
| Not reported | 0 | 1 (0.7) | 0 | 1 (0.7) | 0 |
| Ethnicity, nb (%) | |||||
| Hispanic or Latino | 23 (16.3) | 16 (11.3) | 23 (16.2) | 19 (13.2) | 16 (11.3) |
| Not Hispanic or Latino | 116 (82.3) | 125 (88.7) | 119 (83.8) | 124 (86.1) | 125 (88.7) |
| Not reported | 2 (1.4) | 0 | 0 | 1 (0.7) | 0 |
| Age at vaccination, y | |||||
| Mean (SD) | 35.6 (9.2) | 35.7 (8.7) | 36.0 (8.3) | 36.1 (9.1) | 34.4 (9.2) |
| Median | 39.0 | 38.0 | 37.0 | 38.0 | 35.0 |
| Min, max | 19, 49 | 18, 49 | 18, 49 | 18, 49 | 18, 49 |
Abbreviations: Al(OH)3,aluminum hydroxide; RSVpreF,respiratory syncytial virus stabilized prefusion F subunit vaccine; SD, standard deviation; Tdap,tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed.
No. of participants in the specified vaccine group. These values were used as the denominators for the percentage calculations.
No. of participants in the specified category.